Literature DB >> 8563772

A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.

K Brøsen1, S M de Morais, U A Meyer, J A Goldstein.   

Abstract

It has recently been shown that the most common mutation (named m1) in both Caucasian and Japanese poor metabolizers (PM) of S-mephenytoin is a single base pair mutation (G-->A) in exon 5 of the CYP2C19 gene. In Japanese, a second defective allele of CYP2C19 named m2 consists of a G-->A mutation in exon 4. In the present study, we have investigated the inheritance of the CYP2C19 wild type allele (wt) and the two defective alleles (m1 and m2) in families of 11 Danish PM probands. The study was carried out for two principal reasons. First, we wanted to confirm the autosomal recessive inheritance of the defective alleles, and second, we wanted to examine the specificity and sensitivity of the CYP2C19 genotyping test. Individuals were phenotyped by measuring the ratio of S/R mephenytoin excreted in the urine after administration of mephenytoin, and genotyping was carried out by a PCR-based DNA amplification procedure. The genotypes of nine of the 11 probands were consistent with their phenotypes. Eight were homozygous m1/m1, and one was heterozygous m1/m2. The genotypes of two putative PM probands (wt/m1) were not consistent with their phenotypes. On the basis of extended phenotyping (additional late urine collections (24-36 h) and acidification of urine), one of these could probably be reclassified as an extensive metabolizer (EM) while the other was considered to be a true PM. This suggests the presence of an additional unknown mutant allele in the latter. Seven of the 41 phenotyped relatives in the 11 families were phenotyped as PMs, and with the exception of the father of family 10, their genotypes (m1/m1) were consistent with their phenotypes. Extended phenotyping (acidification of urine) suggested that the father of family 10 in fact is an EM and hence that his genotype (wt/m1) is concordant with his phenotype. Thus, the specificity of genotyping tests for PM was 100%, while the sensitivity was 15/16 or 94%. Our study provides unequivocal evidence for autosomal recessive inheritance of the PM trait.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8563772     DOI: 10.1097/00008571-199510000-00007

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  19 in total

1.  Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.

Authors:  L Bathum; E Skjelbo; T K Mutabingwa; H Madsen; M Hørder; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood.

Authors:  Ersin Gumus; Ozgur Karaca; Melih O Babaoglu; Gökhan Baysoy; Necati Balamtekin; Hulya Demir; Nuray Uslu; Atilla Bozkurt; Aysel Yuce; Umit Yasar
Journal:  Eur J Clin Pharmacol       Date:  2011-11-11       Impact factor: 2.953

3.  Genetic Polymorphism of CYP2C9 Among Sistani Ethnic Group in Gorgan.

Authors:  Abdoljalal Marjani; Aman Mohammad Gharanjik
Journal:  Indian J Clin Biochem       Date:  2017-05-26

Review 4.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

Review 5.  Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.

Authors:  T Yokoi; T Kamataki
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

6.  CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability.

Authors:  T Kita; Y Tanigawara; N Aoyama; T Hohda; Y Saijoh; F Komada; T Sakaeda; K Okumura; T Sakai; M Kasuga
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

7.  CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus.

Authors:  S Kortunay; A Bozkurt; L Bathum; N E Basci; M Calgüneri; K Brøsen; S O Kayaalp
Journal:  Ann Rheum Dis       Date:  1999-03       Impact factor: 19.103

8.  Genetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group.

Authors:  Robabeh Ghiyas Tabari; Abdoljalal Marjani; Ogholdondy Agh Ataby; Azad Reza Mansourian; Nader Mansour Samai
Journal:  Oman Med J       Date:  2013-07

9.  CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.

Authors:  A Ortega-Vázquez; P Dorado; I Fricke-Galindo; H Jung-Cook; N Monroy-Jaramillo; I E Martínez-Juárez; I Familiar-López; E Peñas-Lledó; A LLerena; M López-López
Journal:  Pharmacogenomics J       Date:  2015-06-30       Impact factor: 3.550

10.  Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes.

Authors:  Li-Jun Yang; Lan Fan; Zhao-Qian Liu; Yan-Mei Mao; Dong Guo; Li-Hui Liu; Zhi-Rong Tan; Liang Peng; Chun-Ting Han; Dong-Li Hu; Dan Wang; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2009-01-27       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.